• Strategy execution driving strong revenue growth (ex. CWA)
• Benefits from efficiency and cost management
• Strong cash generation and dividend maintained
• Disciplined capital allocation and strategic investments to support future growth

EBOS delivered strong revenue growth of 9.5% and Underlying EBITDA growth of 7.1% (ex. CWA) in H1 FY25. The Healthcare segment recorded Underlying EBITDA growth of 7.0% (ex. CWA) driven by organic growth across the Community Pharmacy (ex. CWA), TerryWhite Chemmart, and Institutional Healthcare businesses. The Animal Care segment also delivered strong Underlying EBITDA growth of 7.2%. The Group completed three investments in Southeast Asia to strengthen its Medical Technology business, deploying approximately $70 million of capital. EBOS also signed the First Pharmaceutical Wholesaler Agreement with the Australian Government, providing for a modest funding increase from H2 FY25 and a further increase from FY27. The Group reiterated its guidance that it expects to generate Underlying EBITDA between $575 - 600 million in FY25.

EBOS reiterates guidance that the Group expects to generate Underlying EBITDA between $575 - 600 million in FY25.

EBOS continues to execute on its near-term growth strategy, with all initiatives tracking at or above expectations. The Group remains focused on driving organic growth in its Healthcare and Animal Care segments, pursuing new community pharmacy revenue opportunities, delivering cost savings, and pursuing strategic M&A opportunities to strengthen its core and diversify its earnings.